Indivior Plc - Company Profile

Powered by

All the data and insights you need on Indivior Plc in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Indivior Plc Strategy Report

  • Understand Indivior Plc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Indivior Plc: Overview

Select Item

Related keylists

Indivior Plc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectable for the treatment of opioid dependence, and buprenorphine-based injectable suspension, for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses buprenorphine-based products for substance use disorder; and cannabis disorder. Indivior offers products in the form of film, tablets, injectable suspension and nasal spray. It provides its products in the US, Australia, Malaysia, France, Italy; Spain, Germany, Canada, and the UK. Indivior is headquartered in Slough, England, the UK.

 Gain a 360-degree view of Indivior Plc and make more informed decisions for your business Gain a 360-degree view of Indivior Plc and make more informed decisions for your business Find out more
Headquarters United Kingdom
Address 234 Bath Road, Slough, Berkshire, SL14EE
Website www.indivior.com/en
Telephone 8043791090
No of Employees 1,051
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange INDV (LON)
Revenue (2022) $1.1B 21.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 103.8% (2022 vs 2021)
Market Cap* $2.6B
Net Profit Margin (2022) XYZ 103.1% (2022 vs 2021)
* As of and is in US$
View Indivior Plc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Indivior Plc premium industry data and analytics

90+

Clinical Trials

Determine Indivior Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Indivior Plc’s relevant decision makers and contact details.

60+

Catalyst Calendar

Proactively evaluate Indivior Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Marketed Drugs

Understand Indivior Plc’s commercialized product portfolio to stay one step ahead of the market.

20+

Pipeline Drugs

Identify which of Indivior Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

Sales & Consensus Forecasts

Understand the current and future drug revenue for Indivior Plc and assess market opportunity for new entrants with patient population 8-year forecasts.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Indivior Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Opiod Dependence Drugs: Subutex
Suboxone (Sublingual Film/Sublingual Tablet) Suboxone
Subutex (Sublingual Tablet) Sublocade
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Indivior Plc portfolio and identify potential areas for collaboration Understand Indivior Plc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In December, Indivior Inc. along with Indivior UK Limited entered into a settlement agreement with Actavis Laboratories UT to resolve patent disputes of Actavis's Abbreviated New Drug Application for generic buprenorphine and naloxone sublingual film.
2023 Corporate Changes/Expansions In November, the company announced its plans to invest US$60 million in the Raleigh manufacturing plant.
2023 Contracts/Agreements In October, the company secured an exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.’s portfolio of long-acting injectable formulations.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Indivior Plc AstraZeneca Plc Vernalis R&D Ltd Cassava Sciences Inc GW Pharmaceuticals Ltd
Headquarters United Kingdom United Kingdom United Kingdom United States of America United Kingdom
City Slough Cambridge Cambridge Austin Cambridge
State/Province Berkshire England England Texas England
No. of Employees 1,051 89,900 - 29 -
Entity Type Public Public Private Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Graham Hetherington Chairman Executive Board 2020 65
Mark Crossley Chief Executive Officer; Director Executive Board 2020 54
Ryan Preblick Director; Chief Financial Officer Executive Board 2020 48
Jeffrey Burris Chief Legal Officer Senior Management 2021 52
Cynthia Cetani Chief Compliance Officer; Chief Integrity Officer Senior Management 2018 58
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Indivior Plc key executives to enhance your sales strategy Gain insight into Indivior Plc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward